Madrigal Pharmaceuticals, Inc. (MDGL) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 West Conshohocken, PA, 미국. 현재 CEO는 William J. Sibold.
MDGL 을(를) 보유 IPO 날짜 2007-02-06, 528 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $12.04B.
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing innovative therapeutic candidates for cardiovascular, metabolic, and liver diseases. The company's lead product, resmetirom, is a liver-directed selective thyroid hormone receptor-ß agonist currently in Phase III clinical trials for treating non-alcoholic steatohepatitis. Madrigal is also advancing MGL-3745 as a backup compound and has established a research, development, and commercialization partnership with Hoffmann-La Roche. Headquartered in West Conshohocken, Pennsylvania, the company is positioned to address significant unmet medical needs in serious metabolic and hepatic diseases.
